IDEXX Laboratories, Inc. (IDXX) Stock

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is led by CEO Jonathan J. Mazelsky, employs 11,000 people, headquartered in Westbrook, US, publicly traded since 1991.

IDEXX Laboratories, Inc. (IDXX) stock trades at $560.36 with a market capitalization of $44.15B. The stock is valued at a price-to-earnings (P/E) ratio of 36.46, price-to-book of 25.79, price-to-sales of 9.00. Over the past 52 weeks the stock has ranged between $500.61 and $769.98, and currently trades 27.2% below its 52-week high.

On profitability, IDEXX Laboratories, Inc. generates a return on equity (ROE) of 71.96%, above the typical market range of roughly 12-15%, return on capital employed of 67.69%, an operating margin of 31.60%, a net profit margin of 25.03%.

In its most recent fiscal year, IDEXX Laboratories, Inc. reported annual revenue of $4.3B, net profit of $1.1B. Over the last 5 fiscal years, revenue grew at an average annual rate of 9.7%, and net profit grew at an average annual rate of 12.7%. Over that span net profit grew faster than revenue, so net margin widened.

The balance sheet shows a debt-to-equity ratio of 0.68, a current ratio of 1.17, total assets of $3.4B, $180.0M in cash and equivalents.

IDXX has a beta of 1.54 (historically more volatile than the overall market).